reports

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business UpdateCoherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and…

3 weeks ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 06, 2025 16:45 ET  | Source: Neuronetics MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),…

3 weeks ago
Gilat Reports Second Quarter 2025 ResultsGilat Reports Second Quarter 2025 Results

Gilat Reports Second Quarter 2025 Results

Revenues Increased by 37%; GAAP Operating Income of $5.7 Million; Adjusted EBITDA of $11.8 Million Raises Midpoint of 2025 Revenue…

3 weeks ago
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business UpdateLantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted…

3 weeks ago
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:15 ET  | Source: ImageneBio, Inc. SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq:…

3 weeks ago
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:08 ET  | Source: Protara Therapeutics NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…

3 weeks ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:05 ET  | Source: Akebia Therapeutics, Inc. CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®,…

3 weeks ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 16:55 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE)…

4 weeks ago
Pacific Health Care Organization, Inc. Reports its Second Quarter 2025 Financial ResultsPacific Health Care Organization, Inc. Reports its Second Quarter 2025 Financial Results

Pacific Health Care Organization, Inc. Reports its Second Quarter 2025 Financial Results

Irvine, July 31, 2025 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the…

4 weeks ago
e& reports 60.7% increase in consolidated net profit, reaching AED 8.8 billion in H1 2025e& reports 60.7% increase in consolidated net profit, reaching AED 8.8 billion in H1 2025

e& reports 60.7% increase in consolidated net profit, reaching AED 8.8 billion in H1 2025

Q2 consolidated revenue increased to AED 18.0 billion, a 28.1% year-on-year growthQ2 consolidated net profit rises to AED 3.5 billion, backed by…

4 weeks ago